252 related articles for article (PubMed ID: 36574949)
1. Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models.
Tashiro S; Taguchi K; Enoki Y; Matsumoto K
Clin Microbiol Infect; 2023 May; 29(5):616-622. PubMed ID: 36574949
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial Efficacy Evaluations of Metronidazole against Clostridioides difficile Infection using Fecal Pharmacokinetic and Pharmacodynamic Analyses.
Tashiro S; Taguchi K; Enoki Y; Matsumoto K
Pharm Res; 2023 Jul; 40(7):1799-1806. PubMed ID: 37226025
[TBL] [Abstract][Full Text] [Related]
3. Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis.
Okumura H; Fukushima A; Taieb V; Shoji S; English M
J Infect Chemother; 2020 Jan; 26(1):43-50. PubMed ID: 31624029
[TBL] [Abstract][Full Text] [Related]
4. Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials.
Tashiro S; Mihara T; Sasaki M; Shimamura C; Shimamura R; Suzuki S; Yoshikawa M; Hasegawa T; Enoki Y; Taguchi K; Matsumoto K; Ohge H; Suzuki H; Nakamura A; Mori N; Morinaga Y; Yamagishi Y; Yoshizawa S; Yanagihara K; Mikamo H; Kunishima H
J Infect Chemother; 2022 Nov; 28(11):1536-1545. PubMed ID: 35964806
[TBL] [Abstract][Full Text] [Related]
5. Oral teicoplanin administration suppresses recurrence of Clostridioides difficile infection: Proof of concept.
Tanaka Y; Tashiro S; Ikegami S; Enoki Y; Taguchi K; Matsumoto K
Anaerobe; 2023 Dec; 84():102789. PubMed ID: 37879532
[TBL] [Abstract][Full Text] [Related]
6. Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of
Bassères E; Eubank TA; Begum K; Alam MJ; Jo J; Le TM; Lancaster CK; Gonzales-Luna AJ; Garey KW
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0162123. PubMed ID: 38364016
[TBL] [Abstract][Full Text] [Related]
7. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
[TBL] [Abstract][Full Text] [Related]
8. Fidaxomicin inhibits spore production in Clostridium difficile.
Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
[TBL] [Abstract][Full Text] [Related]
9. Fecal concentration of intravenous vancomycin preparation after oral administration in an experimental model: preclinical assay.
Ramos-García J; Robles-Rivera F; Chávez-Soto M; Valdés M; Calzada F; Ortiz-Olvera N
Rev Gastroenterol Mex (Engl Ed); 2023; 88(2):85-90. PubMed ID: 35504831
[TBL] [Abstract][Full Text] [Related]
10. Influence of Binary Toxin Gene Detection and Decreased Susceptibility to Antibiotics among Clostridioides difficile Strains on Disease Severity: a Single-Center Study.
Costa DVS; Pham NVS; Hays RA; Bolick DT; Goldbeck SM; Poulter MD; Hoang SC; Shin JH; Wu M; Warren CA
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0048922. PubMed ID: 35861541
[TBL] [Abstract][Full Text] [Related]
11. The
Wickramage I; Peng Z; Chakraborty S; Harmanus C; Kuijper EJ; Alrabaa S; Smits WK; Sun X
Microbiol Spectr; 2023 Jun; 11(3):e0377722. PubMed ID: 37125917
[TBL] [Abstract][Full Text] [Related]
12. Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model.
Warren CA; van Opstal E; Ballard TE; Kennedy A; Wang X; Riggins M; Olekhnovich I; Warthan M; Kolling GL; Guerrant RL; Macdonald TL; Hoffman PS
Antimicrob Agents Chemother; 2012 Aug; 56(8):4103-11. PubMed ID: 22585229
[TBL] [Abstract][Full Text] [Related]
13. Fidaxomicin for the treatment of
Skinner AM; Scardina T; Kociolek LK
Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
[TBL] [Abstract][Full Text] [Related]
14. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
Ajami NJ; Cope JL; Wong MC; Petrosino JF; Chesnel L
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463537
[No Abstract] [Full Text] [Related]
15. The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin.
Yamaguchi T; Konishi H; Aoki K; Ishii Y; Chono K; Tateda K
J Infect Chemother; 2020 May; 26(5):483-491. PubMed ID: 32165071
[TBL] [Abstract][Full Text] [Related]
16. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
Polivkova S; Krutova M; Capek V; Sykorova B; Benes J
Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906
[TBL] [Abstract][Full Text] [Related]
17. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
Collins DA; Riley TV
Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
[TBL] [Abstract][Full Text] [Related]
18. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.
Sears P; Crook DW; Louie TJ; Miller MA; Weiss K
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S116-20. PubMed ID: 22752859
[TBL] [Abstract][Full Text] [Related]
19. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.
Nerandzic MM; Mullane K; Miller MA; Babakhani F; Donskey CJ
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S121-6. PubMed ID: 22752860
[TBL] [Abstract][Full Text] [Related]
20. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.
Warren CA; van Opstal EJ; Riggins MS; Li Y; Moore JH; Kolling GL; Guerrant RL; Hoffman PS
Antimicrob Agents Chemother; 2013 Feb; 57(2):689-96. PubMed ID: 23147742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
